Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan 23;2008(1):CD005177.
doi: 10.1002/14651858.CD005177.pub2.

Interventions for noisy breathing in patients near to death

B Wee  1 , R Hillier
Affiliations

Interventions for noisy breathing in patients near to death

B Wee et al. Cochrane Database Syst Rev. .

Abstract

Background: Noisy breathing (death rattle) occurs in 23 to 92% of people who are dying. The cause of death rattle remains unproven but is presumed to be due to an accumulation of secretions in the airways. It is therefore managed physically (repositioning and clearing the upper airways of fluid with a mechanical sucker) or pharmacologically (with anticholinergic drugs).

Objectives: To describe and assess the evidence for the effectiveness of interventions used to treat death rattle in patients close to death.

Search strategy: Randomised controlled trials (RCTs), before and after studies and interrupted time series (ITS) studies in adults and children with death rattle were sought by MEDLINE (1966 to 2007), EMBASE (1980 to 2007), CINAHL (1980 to 2007), the Cochrane Pain, Palliative and Supportive Care Trials Register and the Cochrane Central Register of Controlled Trials. In addition, the reference lists of all relevant trials and reports were checked and investigators who are known to be researching this area were contacted for unpublished data or knowledge of the grey literature.

Selection criteria: RCTs, controlled before and after studies and ITS reporting the outcome of pharmacological and non-pharmacological interventions for treating death rattle.

Data collection and analysis: Data was extracted by two independent review authors and trials were quality scored. There was insufficient data to carry out an analysis.

Main results: Thirty studies were identified, of which only one study met the inclusion criteria. This small study was a randomised placebo-controlled trial of the use of hyoscine hydrobromide in patients with death rattle. Hyoscine hydrobromide tended to reduce death rattle compared to placebo but this was not significant. A larger randomised study, comparing atropine, hyoscine butylbromide and scopolamine, is in progress.

Authors' conclusions: There is currently no evidence to show that any intervention, be it pharmacological or non-pharmacological, is superior to placebo in the treatment of death rattle. We acknowledge that in the face of heightened emotions when death is imminent, it is difficult for staff not to intervene. It is therefore likely that the current therapeutic options will continue to be used. However, patients need to be closely monitored for lack of therapeutic benefit and adverse effects while relatives need time, explanation and reassurance to relieve their fears and concerns. There is a need for more well-designed multi-centre studies with objective outcome measures and the ability to recruit sufficient numbers.

PubMed Disclaimer

Conflict of interest statement

None known

Update of

  • doi: 10.1002/14651858.CD005177

References

References to studies included in this review

Clark 2008 {published data only}
    1. Clark K, Currow, DC, Agar M, Fazekas BS, Abernethy AP. A pilot phase II randomized, cross‐over, double‐blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end‐of‐life. Journal of Pain and Palliative Care Pharmacotherapy 2008;22(2):131‐8. - PubMed
Likar 2002 {published data only}
    1. Likar R, Molnar M, Rupacher E, Pipam W, Deutsch J, Mortl M, et al. A clinical study examining the efficacy of scopolamin‐hydrobromide in patients with death rattle (a randomised double‐blind, placebo‐controlled study) [Klinische untersuchung uber die wirkung von scopolamin‐hydrobromicum beim terminalen rasseln (randomisierte, doppelblind, plazebokontrollierte studie)]. Z Palliativmed 2002;3:15‐9.
Likar 2008 {published data only}
    1. Likar R, Rupacher E, Kager H, Molnar M, Pipam W, Sittl R. Comparing the efficacy of glycopyrroniumbromide and scopolamin‐hydrobromide in patients with death rattle. A prospective randomised study [Die Wirkung von Glycopyrroniumbromid im Vergleich mit Scopolamin‐Hydrobromicum bein terminalen Rasseln: Eine randomisierte, doppelblinde Pilotstudie]. The Middle European Journal of Medicine 2008;120:679‐83. - PubMed
Wildiers 2009 {published data only}
    1. Wildiers 2007.
    1. Wildiers H, Dhaeanekint C, Demeulenaere P, Clement PMJ, Desmet M, Nuffelen R, et al. Atropine, hyoscine butylbromide or scopolamine are equally effective for the treatment of death rattle in terminal care. Journal of Pain and Symptom Management 2009;38(1):124‐33. - PubMed

References to studies excluded from this review

Back 2001 {published data only}
    1. Back IN, Jenkins K, Blower A, Beckhelling J. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliative Medicine 2001;15:329‐36. - PubMed
Bennett 1996 {published data only}
    1. Bennett MI. Death rattle: an audit of hyoscine (scopolamine) use and review of management. Palliative Medicine 1996;12(4):229‐33. - PubMed
Bennett 2002 {published data only}
    1. Bennett M, Lucas V, Brennan M, Hughes A, O'Donnell V, Wee B. Using anti‐muscarinic drugs in the management of death rattle: evidence‐based guidelines for palliative care. Palliative Medicine 2002;16:369‐74. - PubMed
Dawson 1989 {published data only}
    1. Dawson HR. The use of transdermal scopolamine in the control of death rattle. Journal of Palliative Care 1989;5(1):31‐3. - PubMed
Ellershaw 2001 {published data only}
    1. Ellershaw JE, Smith C, Overill S, Walker SE, Aldridge J. Care of the dying: setting standards for symptom control in the last 48 hours of life. Journal of Pain and Symptom Management 2001;21(1):12‐7. - PubMed
Elman 2005 {published data only}
    1. Elman LB, Dubin RM, Kelley M, McCluskey L. Management of oropharyngeal and tracheobronchial secretions in patients with neurologic disease. Journal of Palliative Medicine 2005;8(6):1150‐9. - PubMed
Fainsinger 1999 {published data only}
    1. Fainsinger RL. Biochemical dehydration in terminally ill cancer patients. Journal of Palliative Care 1999; Vol. 15, issue 2:59‐61. - PubMed
Hall 2002 {published data only}
    1. Hall P, Weaver L. The last 48 hours of life in long‐term care: a focused chart audit. Journal of American Geriatric Society 2002;50:501‐6. - PubMed
Hugel 2006 {published data only}
    1. Hugel H, Ellershaw J, Gambles M. Respiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. Journal of Palliative Medicine 2006;9(2):279‐84. - PubMed
Hughes 1996 {published data only}
    1. Hughes AC, Wilcock A, Corcoran R. Management of "death rattle". Journal of Pain and Symptom Management 1996; Vol. 12, issue 5:271‐2. - PubMed
Hughes 1997 {published data only}
    1. Hughes A, Wilcock A, Corcoran R. Management of 'death rattle'. Palliative Medicine. 1997; Vol. 11, issue 1:80‐1.
Hughes 2000 {published data only}
    1. Hughes A, Wilcock A, Corcoran R, Lucas V, King A. Audit of three antimuscarinic drugs for managing retained secretions. Palliative Medicine 2000;14:221‐2. - PubMed
Kass 2003 {published data only}
    1. Kass RM, Ellershaw J. Respiratory tract secretions in the dying patient: a retrospective study. Journal of Pain and Symptom Management 2003;26(4):897‐902. - PubMed
Kompanje 2005 {published data only}
    1. Kompanje JO. "The death rattle" in the intensive care unit after withdrawal of mechanical ventilation in neurological patients. Neurocritical Care 2005;3:107‐10. - PubMed
Kompanje 2006 {published data only}
    1. Kompanje EJO. 'Death rattle' after withdrawal of mechanical ventilation: practical and ethical considerations. Intensive and Critical Care Nursing 2006;22:214‐9. - PubMed
Lucas 1994 {published data only}
    1. Lucas V, Burrage H, Mistry A. The use of glycopyrrolate by syringe driver to alleviate bronchial secretions. Progress in Palliative Care 1994; Vol. 2, issue 1:11.
Macleod 2002 {published data only}
    1. Macleod AD. Neurogenic pulmonary oedema in palliative care. Journal of Pain and Symptom Management 2002;23(2):154‐6. - PubMed
Morita 2000 {published data only}
    1. Morita T, Tsunoda J, Inoue S, Chihara S. Risk factors for death rattle in terminally ill cancer patients: a prospective exploratory study. Palliative Medicine 2000;14:19‐23. - PubMed
Morita 2004 {published data only}
    1. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al. Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational study. Journal of Pain and Symptom Management 2004;26(6):533‐9. - PubMed
Murtagh 2002 {published data only}
    1. Murtagh FEM, Thorns A, Oliver DJ. Hyoscine and glycopyrrolate for death rattle. Palliative Medicine 2002; Vol. 16:449‐50. - PubMed
O'Donnell 1998 {published data only}
    1. O'Donnell V. The pharmacological management of respiratory tract secretions. International Journal of Palliative Nursing 1998;4(4):199‐203.
Sorensen 2000 {published data only}
    1. Sorensen HM. Managing secretions in dying patients. Respiratory Care 2000;45(11):1355‐62. - PubMed
Spiess 2003 {published data only}
    1. Spiess JL, Scott SD. Anticholinergic agents for the treatment of "death rattle" in patients with myasthenia gravis. Journal of Pain and Symptom Management 2003;26:684‐6. - PubMed
Spiller 2000 {published data only}
    1. Spiller JA, Fallon M. The use of scopoderm in palliative care. Hospital Medicine 2000;61(11):782‐4. - PubMed
Spruyt 1998 {published data only}
    1. Spruyt O, Kausae A. Antibiotic use for infective terminal respiratory secretions. Journal of Pain and Symptom Management 1998;15(5):263‐4. - PubMed
Stone 2001 {published data only}
    1. Stone P, Rees E, Hardy JR. End of life care in patients with malignant disease. European Journal of Cancer 2001;37:1070‐5. - PubMed
Watts 1997 {published data only}
    1. Watts T, Jenkins K, Back I. Problem and management of noisy rattling breathing in dying patients. International Journal of Palliative Nursing 1997;3(5):245‐52. - PubMed
Wildiers 2002 {published and unpublished data}
    1. Wildiers H, Menten J. Death rattle: prevalence, prevention and treatment. Journal of Pain and Symptom Management 2002;23(4):310‐7. - PubMed

Additional references

Ahmedzai 1998
    1. Ahmedzai S. Palliation of respiratory symptoms. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford Textbook of Palliative Medicine. second. Oxford: Oxford University Press, 1998:583‐616.
Ellershaw 1995
    1. Ellershaw JE, Sutcliffe JM, Saunders CM. Dehydration and the dying patient. Journal of Pain and Symptom Management 1995;10(3):192‐7. - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Lichter 1990
    1. Lichter I, Hunt E. The last 48 hours of life. Journal of Palliative Care 1990;6(4):7‐15. - PubMed
Twycross 1998
    1. Twycross R, Lichter I. The terminal phase. In: Doyle D, Hanks GWC, MacDonald N editor(s). Oxford Textbook of Palliative Medicine. Second Edition. Oxford: Oxford University Press, 1998:977‐92.
Wee 2006
    1. Wee B, Coleman P, Hillier R, Holgate S. The sound of death rattle II: how do relatives interpret the sound?. Palliative Medicine 2006;20(3):177‐81. - PubMed
Wiffen 2005
    1. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD001133.pub2] - DOI - PubMed

Publication types

MeSH terms